Showing 18,381 - 18,400 results of 46,434 for search '(( 5 ((wt decrease) OR (mean decrease)) ) OR ( 50 ((nn decrease) OR (a decrease)) ))', query time: 0.89s Refine Results
  1. 18381
  2. 18382

    Expected changes in obesity after reformulation to reduce added sugars in beverages: A modeling study by Ana Basto-Abreu (5823866)

    Published 2018
    “…On average, 12.6% of the TEI was contributed by added sugars; we defined a 50% reduction in added sugars in SSBs over 10 years as a reformulation target. …”
  3. 18383

    Fiber cell ultrastructure near the bow region up to a depth of 300 μm. by M. Joseph Costello (3043893)

    Published 2016
    “…Note the nucleus is slightly irregular in shape but otherwise normal in appearance with portions of a nucleolus visible. Autophagosomes with double membranes are indicated (yellow arrows), although they decrease in number corresponding to a decrease in membranous organelles in the cytoplasm through this region. …”
  4. 18384

    The efficacy of topical 8% capsaicin patches for the treatment of postsurgical neuropathic pain: a systematic review by Brandon Goodwin (20328988)

    Published 2024
    “…All studies that investigated neuropathic pain area denote a decrease in pain size, with some denoting a continued reduction with subsequent application.…”
  5. 18385

    Prenatal medication use in a prospective pregnancy cohort by pre-pregnancy obesity status by Yassaman Vafai (10294851)

    Published 2021
    “…A total of 17 classes of medications were identified. …”
  6. 18386

    DataSheet_1_A phase I trial of SON-1010, a tumor-targeted, interleukin-12-linked, albumin-binding cytokine, shows favorable pharmacokinetics, pharmacodynamics, and safety in health... by Richard T. Kenney (15289313)

    Published 2024
    “…</p>Methods<p>SB102 (NCT05408572) focused on safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) endpoints. SON-1010 at 50-300 ng/kg or placebo administered subcutaneously on day 1 was studied at a ratio of 6:2, starting with two sentinels; participants were followed through day 29. …”
  7. 18387

    CRISPRi knockdowns of candidate genes and phenotypic characterization of GBS lacking MrvR in amniotic fluid, rich media, and biofilm-promoting growth conditions. by Allison N. Dammann (10271174)

    Published 2021
    “…A qPCR-based multiplex CRISPRi screen using knockdowns of all five candidate genes revealed decreased fitness in amniotic fluid compared to tryptic soy (TS) broth (<b>C</b>); black columns show the competition index of strains bearing individual targeting protospacer plasmids, while red columns show pooled results from both targeting plasmids for each gene. …”
  8. 18388
  9. 18389

    Created with BioRender.com. by Simone Schiavo (15999287)

    Published 2024
    “…Thirteen patients had HFpEF (mean LVEF 55 ± 7%), and seven patients had HFrEF (mean LVEF 35 ± 8%) as well as concomitantly decreased right ventricle function (n = 5), moderate/severe tricuspid regurgitation (n = 3), or pulmonary hypertension (n = 5). …”
  10. 18390

    Hyperbaric oxygen therapy details. by Simone Schiavo (15999287)

    Published 2024
    “…Thirteen patients had HFpEF (mean LVEF 55 ± 7%), and seven patients had HFrEF (mean LVEF 35 ± 8%) as well as concomitantly decreased right ventricle function (n = 5), moderate/severe tricuspid regurgitation (n = 3), or pulmonary hypertension (n = 5). …”
  11. 18391

    Triple immunofluorescence labeling comparing both sarcomeric actin and VDAC expression in control versus MFN2 mutant mice. by Peter Bannerman (3373028)

    Published 2016
    “…Initially, note the selective expression of the mutant form of MFN2 in satellite cells of the mutant myofibers with occasion dissemination into the muscle fiber (white arrow-heads). Also note both the decreased intensity of sarcomeric actin immunolabelling in the mutant mice versus wild-type mice (compare A and B) and the relative disruption of striated myofibrillar distribution of VDAC positive mitochondria in mutant micrograph D versus C. …”
  12. 18392

    Reduction of plasma membrane PtdIns(4)<i>P</i> and PtdIns(4,5)<i>P</i><sub>2</sub> levels and their effect on the Ins<i>P</i><sub>3</sub> and Ca<sup>2+</sup> signals upon hormonal... by Gergő Gulyás (733813)

    Published 2015
    “…After hormonal stimulation (100 nM Ang II), 300 nM rapamycin was added manually to cause acute depletion of PtdIns(4,5)<i>P</i><sub><b>2</b></sub> in the PM. (means ± SE, n = 4). …”
  13. 18393
  14. 18394
  15. 18395
  16. 18396

    The impact of a CTL-based vaccine is dependent upon the extent to which it affects transmission potential. by Helen R. Fryer (194033)

    Published 2011
    “…One vaccine (circles, A and B) considerably reduces transmission probability by a factor of 25 (), but restores life expectancy to its normal value (50 years; years<sup>−1</sup>). …”
  17. 18397
  18. 18398

    UBKIs possess broad antiviral activity, are effective in primary cells, and impose a barrier against resistance development. by Markus Lesch (6475409)

    Published 2019
    “…The experiment was terminated after 8 passages. Data represent mean ± SD of technical replicates.</p>…”
  19. 18399

    Effect of ACE inhibitors on the binding of a set of anti-ACE mAbs to blood ACE. by Maxim N. Petrov (118931)

    Published 2012
    “…Serum pooled from 30 healthy donors and diluted 1/5 in PBS (50 µl) was incubated with or without ACE inhibitors for 1 hour at 37oC and then was incubated overnight with microtiter plate coated with different anti-ACE mAbs (3 µg/ml) via goat-anti-mouse bridge. …”
  20. 18400

    In-Car Nocturnal Blue Light Exposure Improves Motorway Driving: A Randomized Controlled Trial by Jacques Taillard (125714)

    Published 2012
    “…<div><p>Prolonged wakefulness greatly decreases nocturnal driving performance. The development of in-car countermeasures is a future challenge to prevent sleep-related accidents. …”